The UK and US have reached a important commercial pact that will preserve no levies on UK pharmaceutical exports entering the American market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has committed to increase funding on pharmaceuticals through the NHS. This move ensures that import taxes on these key products will stay at zero for a duration of the next three years.
This agreement is in response to earlier statements to hike import taxes on patented pharmaceutical products, with figures discussed as high as double the cost.
"This arrangement between the UK bolsters the global environment for innovative medicines and introduces much-needed equity to U.S.–U.K. pharmaceutical trade," an announcement said.
Economic Importance
Pharmaceuticals are one of the the United Kingdom's most significant export categories to the United States, which is clearly the largest destination for large UK drugmakers.
Statistics reveal that in the one-year period to the end of the third quarter, the UK sold pharmaceutical products valued at £11.1bn to the US. This amount represented 17.4% of all goods exports in that period.
"This deal safeguards jobs, boosts capital expenditure and paves the way for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary remarked.
Key NHS Changes
The deal entails several notable changes from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a aim to increase total NHS spending on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage manufacturers must return to the NHS to stay within budget will be limited at 15%. Last year, repayments were more than 20%.
Industry Background
This agreement takes place against a long-running dispute between the pharmaceutical industry and the British authorities over spending levels and regulatory access.
These tensions were exacerbated by claims that American patients were charged several times more for the equivalent treatments than consumers in the UK and Europe.
In recent months, several major pharmaceutical investments in the UK have been halted or abandoned, while substantial expansions have been directed toward projects in the United States.
The Science Minister acknowledged that the NHS needed to increase expenditure on treatments, noting that its spending on drugs had declined as a percentage of its resources over the last ten years.
